Navigation Links
MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Date:8/19/2007

- Company Further Expands Anti-Interleukin-9 Program with Second Phase 2a

Study -

GAITHERSBURG, Md., Aug. 1 /PRNewswire/ -- MedImmune, Inc. today announced that it has initiated a multi-dose, Phase 2a clinical trial with its monoclonal antibody (MAb) targeting interleukin-9 (IL-9) in adults with mild, persistent asthma. The placebo-controlled, dose-escalation study is designed to evaluate the safety and tolerability of multiple doses of the antibody. This trial is the second Phase 2a study currently underway with the MAb, known as MEDI-528.

"We are excited to advance the investigation of this potential treatment for patients with asthma and to further explore the role of IL-9 in the pathology of this disease," said Barbara White, M.D., vice president, clinical development, inflammatory disease. "Recent preclinical study results have provided new insight about IL-9's role in a host of functions associated with the onset of asthma, including allergic inflammation in the airways and allergen-induced airway modeling. These data further support our hypothesis that an antibody blocking IL-9 may represent a new long-term maintenance or controller therapy for symptomatic, persistent asthma."

Two Phase 1 single-dose, dose-escalation studies have been conducted to evaluate the safety, tolerability and pharmacokinetics of the anti-IL-9 MAb in healthy volunteers. The antibody was well tolerated in both studies. The company is also conducting an ongoing Phase 2a study, initiated in late 2006, to evaluate the efficacy of a single intravenous dose of MEDI-528 and its effect on disease mechanisms in adults with atopic asthma. MedImmune plans to initiate a third Phase 2a study to evaluate the ability of MEDI-528 to inhibit the biological activity of IL-9 in the bronchoalveolar lavage fluid of adult patients with atopic asthma.

About IL-9

As mentioned above, IL-9 has been associated with symptoms of asthma. It is one of at least 29 naturally occurring interleukins in the human body. Overexpression of IL-9 in animal models has been shown to result in many features of asthma, including increased airway inflammation and hyperreactivity. Blocking the actions of IL-9 has been shown to reduce the airway inflammation and increased airway inflammation and increased airway hyperresponsiveness seen in animal models of asthma. MedImmune is conducting research to evaluate the potential to use MAbs targeting IL-9 to treat or prevent symptomatic, moderate-to-severe, persistent asthma.

About Asthma

Asthma is a chronic disease of the airways that may cause wheezing, breathlessness, chest tightness and coughing. According to the U.S. Centers for Disease Control and Prevention (CDC), more than 30 million Americans reported having a history of asthma in 2003, including 9 million children. About 20 million said they currently had asthma. In 2000, the CDC reported that there were more than 10 million asthma-related outpatient visits to private physician offices and hospital clinics. The National Institutes of Health (NIH) have estimated asthma-related healthcare costs in the U.S. at $14 billion annually.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 3,000 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com .


'/>"/>
SOURCE MedImmune, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
8. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
9. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
10. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
11. Malvern initiates European user group meetings for chemical imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... of Australia,s successful biotechnology scientists, Dr ... company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is ... the ASX. Noxopharm is a clinic-ready company with its ... clinical study later this year. ... facing cancer patients - the ability of cancers to become resistant ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology:
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):